Table 1.
Pain in patients with SLE grouped by self-reported SLE-related pain and in controls at year 0 and year 7
| All patients, n = 64 | Patients with low pain, n = 50 (78%) | Patients with decreased pain, n = 7 (11%) | Patients with remaining pain, n = 7 (11%) | Controls, n = 68 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year 0 | Year 7 | p a | Year 0 | Year 7 | p a | Year 0 | Year 7 | p a | Year 0 | Year 7 | p a | Year 0 | Year 7 | p a | ||
| Overall pain, VAS, mmb | 17 (3 to 45) | 23 (6 to 45) | 0.98 | 13 (3 to 23) | 18 (4 to 35) | 0.21 | 67 (51 to 71) | 14 (10 to 44) | 0.031* | 78 (46 to 96) | 64 (52 to 75) | 0.92 | 5 (0 to 29) | 11 (2 to 30) | 0.09 | |
| Changec in overall pain, mmb | – | 0 (− 12 to 15) | – | – | − 1 (− 12 to 6) | – | – | 48 (31 to 61) | – | – | − 0.5 (− 18 to 35) | – | – | − 2(− 13 to 14) | – | |
| SLE-related pain, VAS, mmb | 11 (2 to 31) | 11 (1 to 33) | 0.92 | 7 (1 to 16) | 8 (1 to 22) | 0.19 | 70 (60 to 72) | 15 (2 to 37) | 0.021* | 67 (47 to 83) | 66 (55 to 73) | 0.87 | – | – | – | |
| Changec in SLE-related pain, mmb | – | 1 (− 7 to 7) | – | – | 0 (− 6 to 2) | – | – | 45 (35 to 65) | – | – | − 13(− 20 to 28) | – | – | – | – | |
| Problem SLE-related pain, VAS, mmb | – | 12 (2 to 32) | – | – | 6 (1 to 23) | – | – | 15 (3 to 29) | – | – | 54 (47 to 88) | – | – | – | – | |
| Remaining pain > 3 monthsd | – | 36 (56) | – | – | 25 (50) | – | – | 4 (57) | – | – | 7 (100) | – | – | 34 (50) | – | |
| Chronic widespread pain/ACR90 [31]d | – | 20 (31) | – | – | 13 (26) | – | – | 0 (0) | – | – | 7 (100) | – | – | 9 (13) | – | |
| Number of body regions with pain > three monthsb | – | 7 (4 to 11) | – | – | 6 (4 to 9) | – | – | 4 (3 to 4) | – | – | 11 (9 to 15) | – | – | 3 (2 to 4) | – | |
| Use of analgesics, regulard | – | – | – | – | 12 (24) | – | – | 1 (14) | – | – | 6 (86) | – | – | 6 (7) | – | |
| Use of analgesics, as neededd | – | – | – | – | 18 (36) | – | – | 4 (57) | – | – | 1 (14) | – | – | 41 (48) | – | |
| No use of analgesicsd | – | – | – | – | 20 (40) | – | – | 2 (29) | – | – | 0 (0) | – | – | 39 (45) | – | |
p value defines differences between inclusion (year 0) and follow-up (year 7), – not applicable or not assessed at year 0
aWilcoxon matched pairs test
bMedians with IQR (interquartile range)
cChange between year 0 and year 7
dNumbers (%)
*Statistically significant value